Author:
Hachiya Atsuko,Reeve Aaron B.,Marchand Bruno,Michailidis Eleftherios,Ong Yee Tsuey,Kirby Karen A.,Leslie Maxwell D.,Oka Shinichi,Kodama Eiichi N.,Rohan Lisa C.,Mitsuya Hiroaki,Parniak Michael A.,Sarafianos Stefan G.
Abstract
ABSTRACTDrug combination studies of 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) with FDA-approved drugs were evaluated by two different methods, MacSynergy II and CalcuSyn. Most of the combinations, including the combination of the two adenosine analogs EFdA and tenofovir, were essentially additive, without substantial antagonism or synergism. The combination of EFdA and rilpivirine showed apparent synergism. These studies provide information that may be useful for the design of EFdA combination regimens for initial and salvage therapy assessment.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference32 articles.
1. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel;Thompson;JAMA,2012
2. JamesJS. 2004. FDA approves two combination pills, Epzicom and Truvada; comment on commercial race to once-a-day nucleosides. AIDS Treat News 403:6. http://www.aidsnews.org/2004/08/epzicom-truvada.html.
3. The first once-daily single-tablet regimen for the treatment of HIV-infected patients;Killingley;Drugs Today,2007
4. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine;Borroto-Esoda;Antivir. Ther.,2006
5. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study;Feng;Retrovirology,2009
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献